Therefore, ECHELON-2 trial results are considered to be potentially practice-changing and indicate the potential use of A + CHP treatment in CD30 + PTCL patients. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.